Flowneuroscience
Flow Neuroscience is a Malmo, Sweden medtech company founded in 2016 by clinical psychologist Daniel Mansson and neuroscientist Erik Rehn. It develops a medically approved, at-home transcranial direct current stimulation (tDCS) headset paired with a behavioral-therapy smartphone app to treat major depressive disorder without medication. Its Flow FL-100 device is CE-marked in the EU and UK and received FDA approval (PMA P230024) as the first at-home tDCS treatment for depression, with a US launch planned for September 2026. Flow is backed by Khosla Ventures and other global investors. This is a consumer and clinical medical-device company; no public developer API, OpenAPI, or developer portal was found during enrichment.
Flowneuroscience is profiled on the APIs.io network. Tagged areas include Company, Health, Healthcare, Medical Devices, and Mental Health.
Flowneuroscience’s developer surface includes signup flow and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Get Started 2
Portal, sign-up, and the first successful call
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API